CAMBRIDGE, Mass., May 4, 2021 /PRNewswire/ -- Myeloid
Therapeutics, Inc., a clinical-stage immunology company that is
combining RNA insights with new technology to develop powerful
cancer therapies, today announced that industry veteran
Bruce McCreedy, Ph.D., has joined
the Company as Chief Scientific Officer. Drawing on his wealth of
experience in biopharmaceutical product development, Dr. McCreedy
will lead Myeloid's drug discovery efforts by harnessing its
platform that reprograms innate immune cells to eradicate
disease.
"We are delighted that Bruce is joining us as Chief Scientific
Officer," said Myeloid Chief Executive Officer Daniel Getts, MBA, Ph.D. "As a scientific leader
with deep expertise developing therapies for cancer and autoimmune
diseases, he will play a pivotal role in helping us accelerate
multiple clinical pipeline candidates."
"Myeloid is driving transformative scientific discovery,
advancing multiple product candidates, and building out a deep
preclinical pipeline," said Dr. McCreedy. "I'm thrilled to join at
such an exciting time in Myeloid's development, and I'm eager to
collaborate with my new colleagues to realize the full potential of
myeloid cells as targeted therapeutics to improve outcomes for
patients with serious diseases."
Dr. McCreedy brings decades of industry expertise to Myeloid,
including recent experience helping companies develop successful
novel immuno-oncology products. He served as Senior Vice President,
Cell Therapy and Immuno-Oncology Research at Precision Biosciences
from 2015-2020, where he directed research and development
activities to create multiple, novel off-the-shelf allogeneic
therapies for the treatment of cancer, and to advance three
products into Phase I/II clinical studies. Previously, Dr. McCreedy
served as Executive Vice President and Head of Research and
Development at NexImmune, Inc., where he managed the development of
nanomedicines for the treatment of cancer and autoimmune
diseases.
Earlier in his career, Dr. McCreedy held leadership positions
with Triangle Pharmaceuticals (now Gilead Sciences), where his team
developed the highly successful commercial product known as
FTC/emtricitabine, and Fulcrum Pharma Developments, among other
leading pharmaceutical companies. Dr. McCreedy received a B.S. in
medical microbiology from Wake Forest
University and a Ph.D. in microbiology and immunology from
the Wake Forest University School of
Medicine.
Dr. McCreedy joins Myeloid shortly after the Company launched
with over $50 million in financing
from leading venture companies Newpath Partners, 8VC, Hatteras
Venture Partners, and Alexandria Venture Investments.
About Myeloid Therapeutics
Myeloid Therapeutics is an immunology company that's combining
RNA insights with new technology to develop powerful cancer
therapies. With broad clinical applications possible, the Company
is presently advancing its several product candidates, derived from
its ATAK™ platform technology, with an initial
application in T cell lymphoma and a primed monocyte approach to
treating glioblastoma. The ATAK platform is scalable to multiple
treatment modalities and to other disease areas in collaboration.
For more information, visit https://www.myeloidtx.com/.
Media Contact
Sarah Sutton
Finsbury Glover Hering (FGH)
sarah.sutton@fgh.com
202-337-0808
Ben Waldron
Finsbury Glover Hering (FGH)
ben.waldron@fgh.com
347-622-3740
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myeloid-therapeutics-appoints-leading-immunologist-cell-and-gene-therapy-expert-bruce-mccreedy-phd-as-chief-scientific-officer-301282591.html
SOURCE Myeloid Therapeutics, Inc.